WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein
- PMID: 7700651
WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein
Abstract
The Wilms' tumor suppressor gene, wt1, encodes a transcription factor of the zinc finger family. Mutations in WT1 have been detected in subsets of Wilms' tumor and in patients with the Denys-Drash Syndrome. In order to determine how WT1 regulates transcription and perhaps the consequences that mutations in WT1 may have, we established that residues 85-124 and 181-250 of WT1 constitute domains that function independently with a DNA binding domain to repress or activate transcription, respectively, and function equally effectively with heterologous promoters, suggesting the activator and repressor domains interact with nuclear components of general importance. To seek evidence for such components, increasing concentrations of WT1 repressor domain without a zinc finger DNA binding domain were co-transfected with fixed concentrations of wild-type (wt) WT1 and PDGF A-chain promoter/reporter gene constructs. As levels of the repressor domain were increased, a progressive loss of wt WT1 repressor activity and a progressive increase in its activation were observed, suggesting that the repressor domain of WT1 competes with wt WT1 for an interactive protein that is an essential component of the repressor activity of wt WT1. Because the most common mutation associated with Denys-Drash Syndrome disrupts the zinc finger domains of WT1, the results also suggest that the mutant WT1 may have aberrant DNA binding activity and perhaps function as a dominant negative effector of wt WT1.
Similar articles
-
Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.Oncogene. 1995 Feb 2;10(3):415-22. Oncogene. 1995. PMID: 7845666
-
Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.Biochemistry. 1996 Sep 17;35(37):12070-6. doi: 10.1021/bi960758o. Biochemistry. 1996. PMID: 8810912
-
Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain.Oncogene. 1997 Oct 23;15(17):2001-12. doi: 10.1038/sj.onc.1201391. Oncogene. 1997. PMID: 9366517
-
The role of Wilms' tumor genes.J Med Invest. 1999 Aug;46(3-4):130-40. J Med Invest. 1999. PMID: 10687307 Review.
-
Wilms tumor and the WT1 gene.Exp Cell Res. 2001 Mar 10;264(1):74-99. doi: 10.1006/excr.2000.5131. Exp Cell Res. 2001. PMID: 11237525 Review.
Cited by
-
GRG5/AES interacts with T-cell factor 4 (TCF4) and downregulates Wnt signaling in human cells and zebrafish embryos.PLoS One. 2013 Jul 1;8(7):e67694. doi: 10.1371/journal.pone.0067694. Print 2013. PLoS One. 2013. PMID: 23840876 Free PMC article.
-
Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study.Mol Pathol. 1997 Jun;50(3):138-44. doi: 10.1136/mp.50.3.138. Mol Pathol. 1997. PMID: 9292148 Free PMC article.
-
Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding.Mol Cell Biol. 1998 May;18(5):2768-78. doi: 10.1128/MCB.18.5.2768. Mol Cell Biol. 1998. PMID: 9566896 Free PMC article.
-
Antagonism of WT1 activity by protein self-association.Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11105-9. doi: 10.1073/pnas.92.24.11105. Proc Natl Acad Sci U S A. 1995. PMID: 7479946 Free PMC article.
-
Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9.Biochem J. 2000 Dec 1;352 Pt 2(Pt 2):443-8. Biochem J. 2000. PMID: 11085938 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials